Remicade gets approval, but with mandatory label warning

Johnson & Johnson’s arthritis drug Remicade has got the approval from Federal regulators for wider use with a warning label of lymphoma danger. It is already sold for rheumatoid arthritis.

Now the drug will treat chronic bowel inflammation in children. It will not cure but reduces the symptom and maintains disease cutback. Remicade, known generically as infliximab, comes in a group that represses tumor necrosis factor-alpha, a protein involved in inflammation.


Related Articles

Back to top button